# US Antihelminthics Market

> US Antihelminthics Market Research Report: Size, Share, Trend Analysis By Types (Benzimidazoles, Abamectin, Salicylanilides, Praziquantel, Others), By Applications (Schistosomiasis, Fasciolasis, Filariasis, Angiostrongylosis, Ascariasis, Giardiasis, Others) and By End Users (Hospitals, Clinics, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.46%
- **2024:** $ 365.98 Million
- **2025:** $ 400.6 Million
- **2035:** $ 988.98 Million
- **Key Players:** Boehringer Ingelheim (DE), Merck & Co. (US), Bayer AG (DE), Novartis AG (CH), Sanofi (FR), GlaxoSmithKline (GB), Pfizer Inc. (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US)

**Report ID:** MRFR/Pharma/16367-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-antihelminthics-market-17895

---

## Market Summary

## **US Antihelminthics Market Overview**

As per MRFR analysis, the US Antihelminthics Market Size was estimated at 391.39 (USD Million) in 2023. The US Antihelminthics Market Industry is expected to grow from 450 (USD Million) in 2024 to 1,100 (USD Million) by 2035. The US Antihelminthics Market CAGR (growth rate) is expected to be around 8.465% during the forecast period (2025 - 2035).

### **Key US Antihelminthics Market Trends Highlighted**

The US Antihelminthics Market has been witnessing significant trends driven by increasing awareness of parasitic infections and their implications on health. There has been a notable rise in the prevalence of helminthic infections in regions with less access to sanitation and healthcare, making the development and distribution of effective antihelminthics crucial. The US healthcare system is increasingly focusing on preventative care, which supports the need for medications that can eliminate these parasites before they lead to severe health complications. Additionally, opportunities are emerging through advancements in pharmaceutical technology.

The development of new formulations and delivery systems enhances the efficacy of existing treatments and allows for better patient compliance. Moreover, the growing acceptance of integrative medicine among healthcare providers is creating a space for natural antihelminthics, expanding treatment options available to patients. Recent trends indicate an uptick in research and clinical studies focusing on alternative and combination therapies that may offer broader coverage against multiple helminth species.

Public health initiatives in the US are also ramping up their efforts, leading to increased funding for research and educational campaigns aimed at educating the public about parasitic infections and prevention strategies. Moreover, the rise of telemedicine has facilitated easier access to consultations and prescriptions for antihelminthic treatments, particularly in areas with limited healthcare resources. Overall, these trends signify a proactive approach to addressing helminthic infections in the US, with ongoing opportunities to enhance treatment and prevention strategies.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Antihelminthics Market Drivers**

### **Increasing Prevalence of Helminth Infections**

The rising incidence of helminth infections in the United States is a significant driver for the US Antihelminthics Market Industry. Data from the Centers for Disease Control and Prevention (CDC) reveals that approximately 1.2 million people in the US are diagnosed with parasitic infections each year, including helminths. This represents a continuous prevalence that sustains the demand for antihelminthic treatments.

A particular concern is among children in lower socio-economic regions or those with limited access to healthcare, leading to a greater need for effective antihelminthic medications. Organizations such as the CDC actively promote screenings and treatments, which further increases awareness and demand for these medications. Therefore, the continuous focus on public health initiatives to control and treat helminth infections is expected to drive the market growth of antihelminthic drugs significantly over the coming years.

### **Advancements in Pharmaceutical Research and Development**

Scientific advancements in the field of Research and Development (R&D) are playing a vital role in the growth of the US Antihelminthics Market Industry. The National Institutes of Health (NIH) has been actively funding research into new antihelminthic agents and drug delivery systems, which opens the door to innovative treatments. Such investments lead to the diversification of the drug pipeline, allowing for better-targeted therapies that can address strain resistance among helminths.

As new compounds and formulations are developed, it is anticipated that the market will experience accelerated growth. For instance, the recent approval of novel antihelminthic treatments has shown an improvement in therapeutic outcomes, reflecting the importance of R&D in shaping market trends.

### **Growing Awareness and Education on Parasitic Diseases**

Increased awareness and educational efforts regarding parasitic diseases are proving essential for the expansion of the US Antihelminthics Market Industry. The American Parasitologists Association and similar bodies have been instrumental in providing resources and information aimed at both healthcare professionals and the public. Surveys indicate that educational campaigns have improved the detection rate of helminth infections, driving a higher demand for treatment options.

For example, educational initiatives have contributed to a 30% increase in consultations for suspected helminth infections over the past five years. Consequently, as awareness grows, the demand for antihelminthic medications is likely to rise, enabling continued market growth.

### **Regulatory Support for Antihelminthic Drug Approvals**

Regulatory support and streamlined approval processes for antihelminthic drugs are crucial for market advancement in the US. The Food and Drug Administration (FDA) has enhanced its procedures to expedite the review of new antihelminthic medicines, particularly those addressing evolving resistance patterns. With an average of 15 drugs approved for use annually in complementary areas, this regulatory flexibility stimulates innovation and facilitates market entry for new treatments, thus enhancing overall market growth.

By promoting quicker access to these necessary medications, regulatory agencies positively impact public health outcomes and further reinforce market prospects in the US Antihelminthics Market Industry.

## **US Antihelminthics Market Segment Insights**

### **Antihelminthics Market Type Insights**

The Type segment of the US [Antihelminthics Market](../../../reports/antihelminthics-market-4500) encompasses various important classifications that are crucial in addressing parasitic infections effectively. This market exhibits significant growth driven by a rising awareness of helminthic diseases and advancements in pharmaceutical formulations. Among the types, Benzimidazoles have gained traction due to their broad-spectrum activity against numerous helminths, contributing greatly to public health initiatives nationwide.

Meanwhile, Abamectin is notable for its unique mode of action, providing essential options in the treatment of parasitic infections, especially in veterinary applications. Salicylanilides also present an interesting aspect, primarily used in livestock to combat worm infestations, thereby ensuring better animal health and productivity. Praziquantel stands out in the market as a highly effective treatment for schistosomiasis, a condition affecting a significant portion of the US population and often requiring concerted health strategies for eradication.

The 'Others' category encompasses alternative treatments, reflecting the dynamic nature of the Antihelminthics Market, where continuous innovation plays a critical role in meeting diverse patient needs. The competition among these types fosters a landscape rich in development, supported by research efforts and market players aiming to enhance treatment efficacy while minimizing side effects. The growing prevalence of anti-parasitic resistance poses challenges, but it also motivates ongoing research and the evolution of new classes, further expanding this market segment.

Overall, the Type segment demonstrates a structure geared towards addressing various health concerns, championing advancements in both human and animal health, thereby reinforcing its importance in the US healthcare framework.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Antihelminthics Market Application Insights**

The US Antihelminthics Market segmentation by Application highlights various conditions targeted by antihelminthic treatments, reflecting the diverse requirements of the healthcare sector in the United States. Significant types of infections include Schistosomiasis, which has been a notable concern due to its association with water bodies and sanitation issues, and Fasciolasis, related to the consumption of contaminated food.

Filariasis continues to challenge public health, particularly because of its vector-borne transmission through mosquitoes, emphasizing the importance of preventive measures. Angiostrongylosis represents an emerging threat, especially in areas with high snail populations, while Ascariasis remains prevalent in specific demographic groups. Additionally, Giardiasis adds to the spectrum as a waterborne infection commonly found in recreational areas and affecting various age groups, particularly children.

Each of these applications plays a crucial role in understanding treatment protocols, market dynamics, and future research opportunities within the US Antihelminthics Market. The complexity and variety of these conditions underscore the ongoing necessity for innovation and effective antihelminthic therapies, aiming to enhance public health outcomes and reduce the burden of these parasitic diseases. Insight into these applications not only helps in addressing immediate health concerns but also facilitates strategic planning in resource allocation and healthcare interventions to tackle these infections effectively.

### **Antihelminthics Market End User Insights**

The End User segmentation within the US Antihelminthics Market plays a crucial role in delivering essential treatments for helminth infections across various healthcare settings. Hospitals typically represent a significant portion of the market, as they are equipped to manage both acute and complex cases, providing specialized care to patients with severe infections. Clinics, on the other hand, offer accessibility and convenience for routine treatments, making them essential for the early detection and management of helminthic diseases.

The Other category includes diverse settings like outpatient facilities and community health organizations, contributing to a holistic healthcare approach by expanding treatment access and improving patient outcomes. The rising prevalence of parasitic infections and increased awareness about helminth infections are driving the growth of these segments, while ongoing educational efforts and advancements in treatment methodologies present opportunities for further market expansion. Overall, the diversity in the End User landscape reflects the varied patient needs and the essential nature of antihelminthic therapies in the US healthcare continuum.

## **US Antihelminthics Market Key Players and Competitive Insights**

The US Antihelminthics Market has witnessed significant growth and evolution over the years, driven by an increased awareness of parasitic infections and the consequent demand for effective therapeutic solutions. This market is characterized by diverse product offerings aimed at both human and veterinary applications, focusing on the elimination of helminths that pose health risks to various populations. As competing companies strive to secure a larger market share, they invest in research and development, aiming to innovate and improve existing treatments.

The landscape is marked by the presence of several key players who engage in strategic partnerships, mergers, and acquisitions to enhance their product lines and expand their geographic reach. The competitive dynamics in the market reflect robust strategies tailored toward addressing the unique challenges posed by parasitic diseases in the US.

Merial has established itself as a formidable player in the US Antihelminthics Market, primarily through its robust portfolio of veterinary products. With a strong emphasis on innovation, the company has developed a range of highly effective antihelminthics that cater to the needs of pet owners and livestock producers alike. Merial's ability to leverage its extensive research capabilities allows it to bring forward new formulations and combinations that effectively combat helminthic infections. The company's longstanding reputation for quality and reliability forms a significant part of its strength in the marketplace.

Furthermore, its established distribution channels enable a strong presence across the veterinary sector, allowing Merial to maintain competitive advantages in product accessibility and customer trust.

Vetoquinol also plays an important role in the US Antihelminthics Market, offering products aimed at both livestock and companion animals. The company provides an array of antihelminthics known for their efficacy and safety profiles, achieving wide acceptance in the veterinary community. Vetoquinol's dedication to quality and customer satisfaction has fostered strong relationships with veterinarians and animal producers, contributing to its market positioning. The company's focus on innovation is demonstrated through a consistent introduction of new products designed to enhance the effectiveness of treatment protocols while ensuring animal health and welfare.

Additionally, Vetoquinol has engaged in strategic mergers and acquisitions, strengthening its product portfolio and expanding its market presence in the US. This commitment to growth and customer-focused solutions solidifies Vetoquinol's position as a competitive player in the ever-evolving Antihelminthics landscape.

### **Key Companies in the US Antihelminthics Market Include**

## **US Antihelminthics Market Industry Developments**

The US Antihelminthics Market has recently experienced significant developments, particularly in the wake of increased demand for effective parasitic treatments in animals. Companies such as Merial, Merck, and Zoetis have been intensifying their Research and Development efforts, capitalizing on the growing recognition of parasitic infections in livestock and pets. In September 2023, Merck announced the launch of a novel antihelminthic product aimed at improving efficacy and safety profiles.

Additionally, in August 2023, Elanco Animal Health reported an acquisition of a biotechnology firm focused on antihelminthic solutions, positioning itself to enhance its market offerings and competitive edge. The growth in market valuation for companies like Boehringer Ingelheim and Bayer reflects the heightened awareness and spending on animal health solutions amidst rising veterinary costs. In the past couple of years, the market has witnessed an overall upward trend, with notable advancements in formulations and availability, further driven by consumer demand for high-quality veterinary care.

Regulatory initiatives are also evolving to support innovation in drug development, ensuring that the US remains a pivotal player in the antihelminthics sector.

## **US Antihelminthics Market Segmentation Insights**

### **Antihelminthics Market Type Outlook**

### **Antihelminthics Market Application Outlook**

### **Antihelminthics Market End User Outlook**

## Market Drivers

### Regulatory Support for New Treatments

Regulatory support for the approval of new antihelminthic treatments is another driver influencing the antihelminthics market. The US Food and Drug Administration (FDA) has streamlined the approval process for certain medications, particularly those addressing unmet medical needs. This regulatory environment encourages pharmaceutical companies to invest in the development of new antihelminthic drugs. As a result, the market is likely to see an influx of new products, which could enhance treatment options for patients. The anticipated increase in product availability may lead to a projected market growth of 6% annually, reflecting the positive impact of regulatory support on the antihelminthics market.

### Advancements in Pharmaceutical Research

Recent advancements in pharmaceutical research and development are likely to play a crucial role in shaping the antihelminthics market. Innovative drug formulations and delivery systems are being developed to enhance the efficacy and safety of antihelminthic agents. For instance, the introduction of long-acting formulations may improve patient compliance and treatment outcomes. Furthermore, the US government has been investing in research initiatives aimed at discovering new antihelminthic compounds, which could lead to the emergence of novel therapies. This focus on innovation is expected to stimulate market growth, with the antihelminthics market projected to reach $1 billion by 2027.

### Rising Incidence of Helminth Infections

The rising incidence of helminth infections in the US is a critical factor driving the antihelminthics market. Factors such as climate change and increased travel have contributed to the spread of these infections, particularly in areas where they were previously uncommon. Reports indicate that the prevalence of certain helminth infections has increased by approximately 15% over the past decade. This trend is likely to result in a greater demand for antihelminthic treatments as healthcare providers seek to address the growing burden of these diseases. Consequently, the antihelminthics market is expected to experience robust growth, with an estimated value of $800 million by 2026.

### Growing Awareness of Parasitic Infections

The increasing awareness of parasitic infections among the population appears to be a significant driver for the antihelminthics market. Educational campaigns by health organizations and government agencies have highlighted the risks associated with helminth infections, particularly in vulnerable populations such as children and the elderly. This heightened awareness is likely to lead to increased demand for antihelminthic medications. In 2025, it is estimated that approximately 20 million people in the US are affected by parasitic infections, which could drive the market growth. As more individuals seek treatment, the antihelminthics market is expected to expand, with a projected growth rate of around 5% annually over the next five years.

### Increased Investment in Healthcare Infrastructure

Increased investment in healthcare infrastructure in the US is anticipated to positively impact the antihelminthics market. Enhanced healthcare facilities and improved access to medical services are likely to facilitate better diagnosis and treatment of parasitic infections. Government initiatives aimed at strengthening public health systems may lead to increased screening and treatment efforts for helminth infections. As healthcare providers become more equipped to manage these conditions, the demand for antihelminthic medications is expected to rise. This investment trend could result in a market growth rate of approximately 4% annually, reflecting the potential for improved healthcare delivery in the antihelminthics market.

## Future Outlook

The [Antihelminthics Market](https://www.marketresearchfuture.com/reports/antihelminthics-market-4500) is projected to grow at a 9.46% CAGR from 2025 to 2035, driven by rising parasitic infections, increased awareness, and advancements in drug formulations.

**New opportunities:**

- Development of combination therapies to enhance efficacy and reduce resistance. Expansion of telehealth services for remote consultations and prescriptions. Investment in biodegradable drug delivery systems for environmental sustainability.

By 2035, the antihelminthics market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Benzimidazoles (Largest) vs. Praziquantel (Fastest-Growing)

In the US antihelminthics market, the type segment reveals a competitive landscape with Benzimidazoles holding the largest share, primarily due to their efficacy against a wide range of helminths. Following closely, Praziquantel has emerged as a critical player, showcasing rapid adoption in recent years, driven by its effectiveness against specific parasites. This distribution suggests strong consumer preference towards proven solutions while also highlighting the innovation seen within the market.

Growth trends indicate that while Benzimidazoles remain the dominant force, Praziquantel is rapidly gaining traction as the fastest-growing segment. Factors such as increased awareness about parasitic infections and advancements in drug formulations contribute to Praziquantel's rise. Meanwhile, the emerging focus on veterinary applications also enhances the overall market dynamics, prompting manufacturers to innovate further in this sector.

Benzimidazoles (Dominant) vs. Praziquantel (Emerging)

Benzimidazoles serve as a cornerstone in the antihelminthics landscape, known for their broad-spectrum efficacy and established market presence. They are extensively utilized in both human and veterinary medicine, reflecting their versatility. On the other hand, Praziquantel is rapidly establishing itself as an emerging competitor, particularly known for its targeted action against specific trematodes and cestodes. Its growing acceptance among healthcare providers indicates a shift towards specialized treatments in the market. The contrasting dynamics of these segments highlight a trend where traditional solutions face competition from newer, highly focused alternatives, fostering a diverse product offering to meet varied consumer needs.

### By Application: Ascariasis (Largest) vs. Giardiasis (Fastest-Growing)

Among the various applications in the US antihelminthics market, Ascariasis represents the largest segment, with a significant portion of market share. Other notable conditions include Schistosomiasis and Fasciolasis, which also hold considerable shares but trail behind Ascaris. Giardiasis, while not as large as Ascariasis, is gaining traction, indicating shifts in treatment preferences and public health awareness surrounding parasitic infections. As these conditions vary in prevalence, their respective shares reflect current health trends and healthcare priorities.

The growth trends within this segment are influenced by factors such as increasing awareness of parasitic infections and the rising prevalence of conditions like Giardiasis. The demand for effective antihelminthics is driven by educational initiatives and advancements in diagnostic techniques, which facilitate early detection and treatment. Additionally, the expanding healthcare expenditure in the US supports the development and inclusion of new therapies, promising a more comprehensive approach to managing these infections.

Ascariasis (Dominant) vs. Giardiasis (Emerging)

Ascariasis is the dominant application in the US antihelminthics market, characterized by its widespread prevalence and necessity for effective treatment options. This condition often requires a robust response due to its implications on public health. Ascariasis treatments are well-established, leading to a continuous market presence and loyalty among healthcare providers. In contrast, Giardiasis is emerging rapidly in the market, driven by rising awareness and newly developed therapeutic options. As an emerging condition, Giardiasis reflects the shifts in healthcare focus, highlighting the importance of addressing various parasitic infections. Its increasing recognition and treatment rates indicate a growing segment that healthcare providers are beginning to prioritize, potentially altering future market dynamics.

### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the US antihelminthics market, the distribution of market share among end users reveals that hospitals dominate the segment, accounting for the largest portion due to their capacity to treat a high volume of patients with complex health issues. Clinics, while smaller in market share, are quickly gaining traction as they provide more accessible and convenient care options, catering to outpatient needs, which is crucial for effective helminthic treatments. 

The growth trends in this segment are heavily influenced by an increasing awareness of parasitic infections and rising healthcare expenditure. Factors such as the expansion of healthcare services in urban areas and an increase in preventive healthcare practices have significantly contributed to the growing use of antihelminthics in clinics, making them the fastest-growing segment of end users, reflecting shifts in treatment paradigms towards earlier and more accessible intervention.

Hospitals: Dominant vs. Clinics: Emerging

Hospitals serve as the dominant end user in the US antihelminthics market, equipped with advanced medical infrastructure and a diverse patient base, allowing them to administer a broad spectrum of antihelminthic treatments. Their established networks enable access to critical resources and specialized medical staff, which positions them as the primary choice for comprehensive management of severe cases. Conversely, clinics represent an emerging segment, characterized by their growing role in public health by offering tailored treatment plans and preventive care. They are increasingly adopting antihelminthic medications to effectively address community health needs, supported by the increasing trend of shifting patient care from hospitals to more flexible outpatient settings. This transition signifies a broader movement towards convenience and accessibility in medical treatment.

## Competitive Benchmarking

The antihelminthics market exhibits a dynamic competitive landscape characterized by a blend of innovation, strategic partnerships, and regional expansion. Key players such as Merck & Co. (US), Boehringer Ingelheim (DE), and Pfizer Inc. (US) are actively shaping the market through their distinct operational focuses. Merck & Co. (US) emphasizes research and development, particularly in novel formulations that enhance efficacy against resistant helminth strains. Boehringer Ingelheim (DE) is pursuing strategic collaborations with academic institutions to bolster its pipeline of antihelminthic agents, while Pfizer Inc. (US) is leveraging its extensive distribution network to penetrate emerging markets, thereby enhancing its competitive positioning.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure appears moderately fragmented, with a mix of established players and emerging biotech firms. This fragmentation allows for diverse product offerings, yet the collective influence of major companies like Bayer AG (DE) and Novartis AG (CH) is significant, as they drive innovation and set industry standards.
In October Merck & Co. (US) announced a partnership with a leading agricultural biotech firm to develop a dual-action antihelminthic product aimed at both human and veterinary applications. This strategic move not only diversifies Merck's product portfolio but also positions the company to capitalize on the growing demand for integrated health solutions. The collaboration is expected to enhance research capabilities and accelerate time-to-market for new therapies.
In September Boehringer Ingelheim (DE) launched a new digital platform designed to facilitate real-time data sharing among healthcare providers and researchers. This initiative underscores the company's commitment to digital transformation and aims to improve treatment outcomes through enhanced collaboration. By harnessing data analytics, Boehringer Ingelheim (DE) seeks to refine its product development processes and better address the evolving needs of patients.
In August Pfizer Inc. (US) expanded its manufacturing capabilities in the Midwest, investing approximately $50 million to enhance production efficiency for its antihelminthic products. This expansion is indicative of Pfizer's strategy to ensure supply chain reliability and meet increasing market demand. The investment not only strengthens Pfizer's operational footprint but also reflects a broader trend of companies prioritizing local production to mitigate global supply chain disruptions.
As of November the competitive trends in the antihelminthics market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming pivotal, as companies recognize the value of collaborative innovation in addressing complex health challenges. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on technological advancements, innovative solutions, and robust supply chain management, thereby reshaping the market landscape.

## Recent News & Developments

The US Antihelminthics Market has recently experienced significant developments, particularly in the wake of increased demand for effective parasitic treatments in animals. Companies such as Merial, Merck, and Zoetis have been intensifying their Research and Development efforts, capitalizing on the growing recognition of parasitic infections in livestock and pets. In September 2023, Merck announced the launch of a novel antihelminthic product aimed at improving efficacy and safety profiles.

Additionally, in August 2023, Elanco Animal Health reported an acquisition of a biotechnology firm focused on antihelminthic solutions, positioning itself to enhance its market offerings and competitive edge. The growth in market valuation for companies like Boehringer Ingelheim and Bayer reflects the heightened awareness and spending on animal health solutions amidst rising veterinary costs. In the past couple of years, the market has witnessed an overall upward trend, with notable advancements in formulations and availability, further driven by consumer demand for high-quality veterinary care.

Regulatory initiatives are also evolving to support innovation in drug development, ensuring that the US remains a pivotal player in the antihelminthics sector.

## Report Scope

| MARKET SIZE 2024 | 365.98(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 400.6(USD Million) |
| MARKET SIZE 2035 | 988.98(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.46% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Boehringer Ingelheim (DE), Merck & Co. (US), Bayer AG (DE), Novartis AG (CH), Sanofi (FR), GlaxoSmithKline (GB), Pfizer Inc. (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US) |
| Segments Covered | Type, Application, End User |
| Key Market Opportunities | Emerging biopharmaceutical innovations enhance efficacy and safety in the antihelminthics market. |
| Key Market Dynamics | Rising demand for novel antihelminthics driven by regulatory changes and increasing consumer awareness of parasitic infections. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US antihelminthics market in 2024?**
A: The overall market valuation was $365.98 Million in 2024.

**Q: What is the projected market valuation for the US antihelminthics market by 2035?**
A: The projected valuation for 2035 is $988.98 Million.

**Q: What is the expected CAGR for the US antihelminthics market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period 2025 - 2035 is 9.46%.

**Q: Which companies are considered key players in the US antihelminthics market?**
A: Key players include Boehringer Ingelheim, Merck & Co., Bayer AG, Novartis AG, Sanofi, GlaxoSmithKline, Pfizer Inc., Bristol-Myers Squibb, and Eli Lilly and Company.

**Q: What are the main segments of the US antihelminthics market?**
A: The main segments include type, application, and end user.

**Q: How did the Benzimidazoles segment perform in 2024?**
A: The Benzimidazoles segment was valued between $100.0 Million and $250.0 Million in 2024.

**Q: What is the valuation range for the Praziquantel segment in 2024?**
A: The Praziquantel segment had a valuation range of $70.0 Million to $180.0 Million in 2024.

**Q: Which application segment had the highest valuation in 2024?**
A: The 'Others' application segment had a valuation range of $170.98 Million to $398.98 Million in 2024.

**Q: What is the projected growth for the Hospitals end user segment by 2035?**
A: The Hospitals end user segment is projected to grow from $146.39 Million to $385.12 Million by 2035.

**Q: What is the expected performance of the Filariasis application segment in the coming years?**
A: The Filariasis application segment is expected to grow from a valuation of $50.0 Million to $130.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-antihelminthics-market-17895*